Dr. Roila on Aprepitant for the Prevention of Cisplatin-Induced Delayed Emesis

Fausto Roila, MD
Published: Friday, Jun 27, 2014

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis that was presented at the 2014 MASCC/ISOO International Symposium.

This analysis compared aprepitant, an NK1 receptor inhibitor, and dexamethasone to metoclopramide and dexamethasone for the prevention of delayed emesis. In a previous analysis, aprepitant demonstrated benefit on day 1 and day 2-5. However, the benefit experienced on day 2-5 with aprepitant may be a continuation of the initial benefit induced on day 1, Roila suggests.

In this analysis, the benefit was essentially the same on day 1 between patients receiving aprepitant plus dexamethasone and those receiving metoclopramide plus dexamethasone. On day 2-5, complete response rate was not significantly different: 80.3% in the aprepitant arm compared with 82.5% in the metoclopramide arm. Secondary endpoints were also similar, suggesting that neither therapy is superior.

<<< View more from the 2014 MASCC/ISOO Symposium

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis that was presented at the 2014 MASCC/ISOO International Symposium.

This analysis compared aprepitant, an NK1 receptor inhibitor, and dexamethasone to metoclopramide and dexamethasone for the prevention of delayed emesis. In a previous analysis, aprepitant demonstrated benefit on day 1 and day 2-5. However, the benefit experienced on day 2-5 with aprepitant may be a continuation of the initial benefit induced on day 1, Roila suggests.

In this analysis, the benefit was essentially the same on day 1 between patients receiving aprepitant plus dexamethasone and those receiving metoclopramide plus dexamethasone. On day 2-5, complete response rate was not significantly different: 80.3% in the aprepitant arm compared with 82.5% in the metoclopramide arm. Secondary endpoints were also similar, suggesting that neither therapy is superior.

<<< View more from the 2014 MASCC/ISOO Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x